Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney...

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Pharmacology

Background:

• Chronic kidney disease (CKD) is a prevalent condition associated with kidney failure and cardiovascular disease.
• Proteinuria is a significant independent risk factor for CKD progression and cardiovascular complications.
• Renin-angiotensin-aldosterone system (RAAS) blockers are primary agents for reducing proteinuria and protecting kidneys.

Purpose of the Study:

• To evaluate the efficacy and safety of supratherapeutic doses of RAAS blockers compared to standard doses in CKD patients.
• To determine if higher RAAS blocker doses offer improved renoprotection by reducing proteinuria.

Main Methods:

• Review of clinical trial data comparing standard versus supratherapeutic doses of RAAS blockers (angiotensin receptor blockers, ACE inhibitors).
• Analysis focused on proteinuria reduction, safety, and tolerability in diabetic and non-diabetic CKD populations.

Main Results:

• Supratherapeutic dosing of RAAS blockers demonstrated favorable safety and tolerability profiles.
• Higher doses were effective in significantly reducing proteinuria in both diabetic and non-diabetic CKD patients.
• Efficacy in proteinuria reduction may be limited at currently recommended standard doses for hypertension.

Conclusions:

• Using supratherapeutic doses of RAAS blockers represents a potentially valuable strategy for optimizing proteinuria reduction in CKD.
• This approach may enhance renoprotection beyond the effects achieved with standard dosing regimens.
• Further research into supratherapeutic dosing could lead to improved therapeutic outcomes for CKD management.